- Home
- ALLR vs TNON Comparison
ALLR vs TNON Comparison
Compare ALLR & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- TNON
- Stock Information
- Founded
- ALLR 2004
- TNON 2012
- Country
- ALLR United States
- TNON United States
- Employees
- ALLR N/A
- TNON N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- TNON Medical Specialities
- Sector
- ALLR Health Care
- TNON Health Care
- Exchange
- ALLR Nasdaq
- TNON Nasdaq
- Market Cap
- ALLR 2.3M
- TNON 2.2M
- IPO Year
- ALLR N/A
- TNON 2022
- Fundamental
- Price
- ALLR $1.32
- TNON $2.71
- Analyst Decision
- ALLR
- TNON Strong Buy
- Analyst Count
- ALLR 0
- TNON 2
- Target Price
- ALLR N/A
- TNON $16.00
- AVG Volume (30 Days)
- ALLR 658.4K
- TNON 1.5M
- Earning Date
- ALLR 11-14-2024
- TNON 11-13-2024
- Dividend Yield
- ALLR N/A
- TNON N/A
- EPS Growth
- ALLR N/A
- TNON N/A
- EPS
- ALLR N/A
- TNON N/A
- Revenue
- ALLR N/A
- TNON $3,315,000.00
- Revenue This Year
- ALLR N/A
- TNON $51.09
- Revenue Next Year
- ALLR N/A
- TNON $88.88
- P/E Ratio
- ALLR N/A
- TNON N/A
- Revenue Growth
- ALLR N/A
- TNON 38.30
- 52 Week Low
- ALLR $1.26
- TNON $2.61
- 52 Week High
- ALLR $666.00
- TNON $20.00
- Technical
- Relative Strength Index (RSI)
- ALLR 32.39
- TNON 33.99
- Support Level
- ALLR $1.32
- TNON $3.22
- Resistance Level
- ALLR $1.53
- TNON $3.57
- Average True Range (ATR)
- ALLR 0.12
- TNON 0.25
- MACD
- ALLR 0.05
- TNON -0.05
- Stochastic Oscillator
- ALLR 14.63
- TNON 6.55
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.